ClinicalTrials.gg
RecruitingNCT06778863GUARDIAN-101Updated Feb 13, 2026

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

A Phase 1 interventional study of CLSP-1025 in Advanced Solid Tumor, Unresectable Solid Tumor and Metastatic Solid Tumor, sponsored by Clasp Therapeutics, Inc.. Recruiting at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Clasp Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 2,056 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
565th of 1,865
90 · median 43
Started
2025
with 84 others
Phase 1
710 of 2,056
128 open now
Primary completion
2027-12
later than 324 of 541 live
Registered
1,909th of 2,056
by date

Among the 2,056 studies in Neoplasm Metastasis with a site in United States, this one is the 565th largest by planned enrollment of the 1,865 interventional ones that give a count, is one of 85 that started in 2025, is one of 710 in phase 1, reaches primary completion later than 324 of the 541 other live ones, and was the 1,909th registered.

Neoplasm Metastasis

4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,056 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,056 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

Read the detailed description

This Phase 1, open-label, multicenter study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of CLSP-1025 when administered to HLA-A*02:01-positive adult patients with advanced solid tumors that harbor the p53 R175H mutation. The study will be conducted in 2 parts: Part A Monotherapy Dose Escalation to determine the recommended dose(s) for expansion (RDE[s]) and Part B Monotherapy Expansion to explore the preliminary antitumor activity as well as further characterize the safety, tolerability, PK, and PD of CLSP-1025 at the RDE(s).

03

Conditions studied

  • Advanced Solid Tumor
  • Unresectable Solid Tumor
  • Metastatic Solid Tumor
  • Colorectal Adenocarcinoma
  • Pancreatic Adenocarcinoma
  • Lung Cancer
  • Ovarian Cancer
  • Breast Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Prostate Cancer
  • Bladder Cancer

Keywords

  • CLSP-1025
  • T Cell Engager
  • TCE
  • TP53
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients must be at least 18 years of age at the time of signing the .
  • Patients must be willing and able to provide written informed consent
  • Patients must have locally advanced or solid tumors that have progressed after standard of care therapy or for which no standard therapy exists
  • Tumors must harbor a TP53 R175H variant mutation confirmed by an accredited laboratory-based test
  • Patients must be HLA-A*02:01 positive by central assay
  • (ECOG) performance status of 0 to 1 at the time of enrollment
  • Adequate hematological, renal and hepatic function
  • Per Investigator judgement, patient is willing and able to complete study visits and/or procedures per the protocol and comply with study requirements for study participation

Key Exclusion Criteria:

  • Patients with Li-Fraumeni syndrome or other known germline p53 R175H mutation
  • Patients who have received other p53 R175H-directed therapies
  • Patients who have not fully recovered from adverse events due to previous anticancer therapies
  • Patients with active infection requiring systemic antimicrobial therapy
  • Any other primary within the 2 years prior to enrollment (except for non- melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or prostate cancer in remission.
  • Known active central nervous system metastases and/or carcinomatous meningitis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Part A: Monotherapy Dose Escalation of CLSP-1025

    Dose escalation of CLSP-1025 in HLA-A\*02:01-positive adult patients with advanced solid tumors that harbor the p53 R175H mutation

    Drug: CLSP-1025

  • Experimental
    Part B: Monotherapy Dose Expansion of CLSP-1025

    Dose expansion of CLSP-1025 in HLA-A\*02:01-positive adult patients with advanced solid tumors that harbor the p53 R175H mutation

    Drug: CLSP-1025

Interventions

  • DrugCLSP-1025

    CLSP-1025 will be administered by IV infusion

06

What researchers measure

Primary outcomes

  1. Part A: Determine the maximum tolerated dose (MTD) and/or the recommended dose(s) for expansion (RDE[s])

    Rate of dose-limiting toxicities (DLTs) after infusion of CLSP-1025

    Time frame: 28 days after infusion

  2. Part B: Evaluate the Objective response rate (ORR) of CLSP-1025 as a monotherapy in HLA-selected patients with advanced solid tumors that express the p53 R175H mutation

    Objective response rate (ORR) per RECIST V1.1 determined by Investigator assessment

    Time frame: Up to 24 months after infusion

Secondary outcomes

  1. Number of patients with treatment-emergent adverse events, as assessed by CTCAE, v5.0

    Incidence and severity of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 24 months after infusion

  2. Number of patients with treatment-related adverse events, as assessed by CTCAE, v5.0

    Incidence and severity of treatment-related adverse events (TRAEs)

    Time frame: Up to 24 months after infusion

  3. Number of patients with clinically significant changes in QTcF Interval

    Incidence of clinically significant changes in QTcF Interval

    Time frame: Up to 24 months after infusion

  4. Maximum plasma concentration (Cmax) of CLSP-1025

    To determine the maximum plasma concentration (Cmax) of CLSP-1025

    Time frame: Pre-dose and up to 168 hours post-dose

  5. Minimum plasma concentration (Cmin) of CLSP-1025

    To determine the minimum plasma concentration (Cmin) of CLSP-1025

    Time frame: Pre-dose and up to 168 hours post-dose

  6. Area under the curve at the end of the dosing interval (AUCtau) of CLSP-1025

    To determine the area under the curve at the end of the dosing interval (AUCtau) of CLSP-1025

    Time frame: Pre-dose and up to 168 hours post-dose

  7. Half-life (t1/2) of CLSP-1025

    To determine the half-life (t1/2) of CLSP-1025

    Time frame: Pre-dose and up to 168 hours post-dose

  8. Assess the immunogenicity of CLSP-1025

    To determine the presence of anti-CLSP-1025 antibodies at baseline and on treatment

    Time frame: Up to 24 months after infusion

  9. Part A: Objective Response Rate (ORR)

    Determine Objective Response Rate (ORR) per RECIST V1.1

    Time frame: Up to 24 months after infusion

  10. Duration of response (DOR)

    Determine DOR of CLSP-1025 until radiographic disease progression per RECIST V1.1 or death

    Time frame: Up to 24 months after infusion

  11. Time to Response

    Determine time to response of CLSP-1025 per RECIST V1.1.

    Time frame: Up to 24 months after infusion

  12. Disease Control Rate

    Determine disease control rate of CLSP-1025 per RECIST V1.1.

    Time frame: Up to 24 months after infusion

  13. Progression-free survival (PFS)

    Determine PFS of CLSP-1025 until radiographic disease progression per RECIST V1.1 or death.

    Time frame: Up to 24 months after infusion

  14. Time of Treatment

    Determine Time on Treatment of CLSP-1025 from first dose to last dose

    Time frame: Up to 24 months after infusion

  15. Overall Survival (OS)

    Determine OS of CLSP-1025 until death

    Time frame: Up to 24 months after infusion

07

Study locations

21 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 34 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 16, 2025
StartActual
Feb 28, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06778863
Lead sponsor
Clasp Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 16, 2025
Start date
Feb 28, 2025
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Feb 13, 2026

Study contacts

Lauren Harshman, MD
Contact
LHarshman@clasptx.com
+1-617-812-1431

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion